Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Core Insights - Inhibrx Biosciences, Inc. will host a live webcast on October 23, 2025, to present topline results from the ChonDRAgon study of ozekibart (INBRX-109) for advanced chondrosarcoma [1] - The company will also provide updates on ongoing trials of ozekibart in combination therapies for colorectal cancer and Ewing sarcoma [1] Company Overview - Inhibrx is a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases [1][5] - The company utilizes diverse protein engineering methods to create novel biologic therapeutic candidates [5] Product Information - Ozekibart (INBRX-109) is a tetravalent death receptor 5 (DR5) agonist antibody designed to induce tumor-biased cell death [3] - The FDA granted Fast Track designation for ozekibart in January 2021 and orphan drug designation in November 2021 for chondrosarcoma [3] Clinical Trials - A Phase 2 trial of ozekibart in metastatic, unresectable conventional chondrosarcoma was initiated in June 2021 [4] - Ongoing Phase 1/2 trials are investigating ozekibart in combination with FOLFIRI for colorectal cancer and with irinotecan/temozolomide for Ewing sarcoma [4]